Serum tumour markers in patients with chronic kidney disease

References

• Berzinec P., Zuffova H., Letkovicova M., Arpasova M. Serum tumor marker CYFRA 21‐1 in the diagnostics of squamous cell lung cancer – comparison with CEA. Neoplasma 1996; 43: 159–61
   PubMed Web of Science ®Google Scholar
• Villena V., Lopez‐Encuentra A., Echave‐Sustaeta J., Martin‐Escribano P., Ortuno‐de‐Solo B., Estenoz‐Alfaro J. Diagnostic value of CA 72–4, carcinoembryonic antigen, CA 15‐3, and CA 19‐9 assay in pleural fluid. A study of 207 patients. Cancer 1996; 78: 736–40
   PubMed Web of Science ®Google Scholar
• Diez M., Torres A., Maestro M. L., Ortega M. D., Gomez A., Pollan M., et al. Prediction of survival and recurrence by serum and cytosolic levels of CEA, CA125 and SCC antigens in resectable non‐small‐cell lung cancer. Br J Cancer 1996; 73: 1248–54
   PubMed Web of Science ®Google Scholar
• Kiss B., Magyarlaki T., Buzogany I., Fazekas A., Sukosd F., Nagy J. Paraneoplastic nephropathy associated with adult renal carcinoma. Orvosi Hetilap 1999; 10,140: 75–80
   Google Scholar
• Kumar S. K., Sohal P. M., Kohli H. S., Sud K., Gupta K. L., Joshi K., et al. Acute renal failure due to cast nephropathy in nonsecretory myeloma: a case report and review of the literature. Int Urol Nephrol 2005; 37: 351–3
   PubMedGoogle Scholar
• Chen K. J., Jan Y. J., Chen C. H., Cheng C. H., Wu M. J., Shu K. H. Multiple myeloma‐associated cast nephropathy with crystal structure: case report and review of the literature. Nephrology 2005; 10: 594–6
   PubMed Web of Science ®Google Scholar
• Dogan E., Izmirli M., Ceylan K., Erkoc R., Sayarlioglu H., Begenik H., et al. Incidence of renal insufficiency in cancer patients. Advances in Therapy 2005; 22: 357–62
   PubMed Web of Science ®Google Scholar
• Eneman J. D., Philips G. K. Cancer management in patients with end‐stage renal disease. Oncology (Huntington) 2005; 19: 1199–212
   PubMed Web of Science ®Google Scholar
• Humphreys B. D., Soiffer R. J., Magee C. C. Renal failure associated with cancer and its treatment: an update. J Am Soc Nephrol 2005; 16: 151–61
   PubMed Web of Science ®Google Scholar
• Nomura F., Koyama A., Ishijima M., Takano S., Narita M., Nakai T. Serum levels of five tumor markers for lung cancer in patients with chronic renal failure. Oncol Rep 1998; 5: 389–92
   PubMed Web of Science ®Google Scholar
• Filella X., Cases A., Molina R., Jo J., Bedini J. L., Revert L., et al. Tumor markers in patients with chronic renal failure. Int J Biol Markers 1990; 5: 85–8
   PubMedGoogle Scholar
• Arik N., Adam B., Akpolat T., Hasil K., Tabak S. Serum tumour markers in renal failure. Int Urol Nephrol 1996; 28: 601–4
   PubMedGoogle Scholar
• Lehtovirta P., Apter D., Stenman U. H. Serum CA 125 levels during the menstrual cycle. Br J Obstet Gynaecol 1990; 97: 930–3
   PubMedGoogle Scholar
• Kan Y. Y., Yeh S. H., Ng H. T., Lou C. M. Effect of menstruation on serum CA125 levels. Asia–Oceania J Obst Gynaecol 1992; 18: 339–43
   PubMedGoogle Scholar
• Harper L., McIntyre C. W., MacDougall I. C., Meyer P., Raine A. E., Baker L. R. Prostate‐specific antigen levels in patients receiving long‐term dialysis. Br J Urol 1995; 76: 482–3
   PubMedGoogle Scholar
• Sumura M., Yokogi H., Beppu M., Honda H. Diagnostic value of serum prostate‐specific antigen in hemodialysis patients. Int J Urol 2003; 10: 247–50
   PubMed Web of Science ®Google Scholar
• Bruun L., Bjork T., Lilja H., Becker C., Gustafsson O., Christensson A. Percent‐free prostate specific antigen is elevated in men on haemodialysis or peritoneal dialysis treatment. NDT 2003; 18: 598–603
   PubMed Web of Science ®Google Scholar
• Sasagawa I., Kubota Y., Hayami S., Adachi M., Nakada T., Miura H., et al. Serum levels of total and free prostate specific antigen in men on hemodialysis. J Urol 1998; 160: 83–5
   PubMed Web of Science ®Google Scholar
• Danisman A., Kilic S., Kukul E., Yakupoglu G., Guntekin E., Baykara M., et al. Do renal failure and hemodialysis have any effect on the elimination of free and total prostate‐specific antigen?. Eur Urol 2000; 37: 579–81
   PubMed Web of Science ®Google Scholar
• Docci D., Turci F., Pistocchi E. High levels of carcinoembryonic antigen (CEA) in the serum of uremic patients under hemodialysis treatment. Quad Sclavo Diagnostica 1984; 20: 435–9
   PubMedGoogle Scholar
• Ammon A., Eiffert H., Weber M. H., Rummel J., Niemann J. Tumor markers in dialysis‐dependent renal failure. A comparison of the mucin‐like carcinoma antigen, CA15‐3, CA125, CA19‐9 and CEA antigens. Onkologie 1988; 11: 260–2
   PubMedGoogle Scholar
• Lye W. C., Tambyah P., Leong S. O., Lee E. J. Serum tumor markers in patients on dialysis and kidney transplantation. Adv Peritoneal Dialysis 1994; 10: 109–11
   PubMedGoogle Scholar
• Zeferos N., Digenis G. E., Christophoraki M., Alexopoulos I., Kostakis A., Gyftaki H., et al. Tumor markers in patients undergoing hemodialysis or kidney transplantation. Nephron 1991; 59: 618–20
   PubMed Web of Science ®Google Scholar
• Cases A., Filella X., Molina R., Ballesta A. M., Lopez‐Pedret J., Revert L. Tumor markers in chronic renal failure and hemodialysis patients. Nephron 1991; 57: 183–6
   PubMed Web of Science ®Google Scholar
• Nakahama H., Tanaka Y., Fujita Y., Fujii M., Sugita M. Tumor markers of lung cancer are elevated in chronic renal failure patients. Respirology 1998; 3: 207–10
   PubMedGoogle Scholar